Skip to main content

FDA Approvals

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma

Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease

Page 6 of 20
Results 51 - 60 of 200